| $385M | ||
| $350M | ||
| $215M | ||
| $100M | ||
| $83M | ||
| $63M |
Buys | $0 | 0 | 0 |
Sells | $4,035,521 | 9 | 100 |
| SANDERS MACHELLE | director | 0 | $0 | 1 | $68,544 | $-68,544 |
| HEGGIE THERESA | director | 0 | $0 | 2 | $1.1M | $-1.1M |
| Barnes Alane P | Chief Legal Officer | 0 | $0 | 6 | $2.87M | $-2.87M |
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Over the last 12 months, insiders at BioCryst Pharmaceuticals, Inc. have bought $0 and sold $4.04M worth of BioCryst Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at BioCryst Pharmaceuticals, Inc. have bought $789,891 and sold $4.47M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 7,861 shares for transaction amount of $49,996 was made by LEVIN ALAN G (director) on 2024‑05‑30.
| 2026-03-20 | Sale | HEGGIE THERESA | director | 49,933 0.0248% | $10.11 | $504,823 | -7.00% | |
| 2026-03-16 | Sale | Barnes Alane P | Chief Legal Officer | 150,000 0.0703% | $9.15 | $1.37M | +4.06% | |
| 2025-12-22 | Sale | Barnes Alane P | Chief Legal Officer | 21,773 0.0104% | $7.65 | $166,563 | +0.13% | |
| 2025-12-15 | Sale | Barnes Alane P | Chief Legal Officer | 21,210 0.0101% | $7.65 | $162,257 | +0.07% | |
| 2025-12-03 | Sale | Barnes Alane P | Chief Legal Officer | 19,770 0.0092% | $7.65 | $151,241 | -3.18% | |
| 2025-12-02 | Sale | Barnes Alane P | Chief Legal Officer | 50,906 0.0244% | $7.21 | $367,216 | +6.28% | |
| 2025-12-01 | Sale | Barnes Alane P | Chief Legal Officer | 91,004 0.0431% | $7.10 | $646,511 | +6.59% | |
| 2025-11-13 | Sale | SANDERS MACHELLE | director | 9,600 0.0047% | $7.14 | $68,544 | +9.71% | |
| 2025-08-13 | Sale | HEGGIE THERESA | director | 70,000 0.0333% | $8.51 | $595,868 | -11.37% | |
| 2024-12-13 | Sale | Hutson Nancy J | director | 7,000 0.0034% | $7.54 | $52,780 | +5.71% | |
| 2024-06-24 | Sale | McKee Amy E | director | 8,600 0.0042% | $6.32 | $54,352 | +23.52% | |
| 2024-06-17 | Sale | SANDERS MACHELLE | director | 4,689 0.0021% | $6.00 | $28,134 | +23.88% | |
| 2024-06-14 | Sale | HEGGIE THERESA | director | 6,698 0.0031% | $6.11 | $40,925 | +25.28% | |
| 2024-05-30 | LEVIN ALAN G | director | 7,861 0.0037% | $6.36 | $49,996 | +16.74% | ||
| 2024-05-24 | ASELAGE STEVE | director | 2,500 0.0012% | $6.40 | $16,000 | +24.63% | ||
| 2024-05-20 | Hutson Nancy J | director | 5,000 0.0025% | $6.38 | $31,900 | +24.47% | ||
| 2024-05-20 | MILANO VINCENT | director | 15,000 0.0074% | $6.25 | $93,750 | +24.47% | ||
| 2024-05-14 | Thackray Helen M. | Chief R&D Officer | 30,000 0.0159% | $5.86 | $175,800 | +42.26% | ||
| 2024-05-14 | Doyle Anthony | Chief Financial Officer | 36,300 0.0183% | $5.57 | $202,191 | +42.26% | ||
| 2024-05-13 | Stonehouse Jon P | President & CEO | 30,000 0.0143% | $5.55 | $166,500 | +35.35% |
| Barnes Alane P | Chief Legal Officer | 400703 0.1909% | $3.96M | 2 | 14 | +76.79% |
| HEGGIE THERESA | director | 65352 0.0311% | $646,331.28 | 1 | 3 | +118.24% |
| SANDERS MACHELLE | director | 30642 0.0146% | $303,049.38 | 0 | 3 | |
| BAKER FELIX | 10 percent owner | 4832285 2.3023% | $47.79M | 1 | 0 | +60.41% |
| Baker Brothers Life Sciences Capital (GP), LLC | 10 percent owner | 3831534 1.8255% | $37.89M | 3 | 3 | +289.09% |
| BAKER BROS. ADVISORS LP | 10 percent owner | 1551387 0.7391% | $15.34M | 11 | 3 | <0.0001% |
| Baker Biotech Capital (GP), LLC | 10 percent owner | 1522015 0.7251% | $15.05M | 3 | 3 | +289.09% |
| BVF PARTNERS L P/IL | Indirect Beneficial Owner | 1455900 0.6936% | $14.4M | 0 | 1 | |
| Stonehouse Jon P | President & CEO | 1127770 0.5373% | $11.15M | 14 | 8 | +33.41% |
| GORDON CARL L | director | 1100000 0.5241% | $10.88M | 0 | 1 | |
| SHERRILL JOSEPH H JR | director | 492000 0.2344% | $4.87M | 5 | 0 | +141.01% |
| Gayer Charles K | Chief Commercial Officer | 307533 0.1465% | $3.04M | 1 | 1 | +35.35% |
| Babu Yarlagadda S | Chief Discovery Officer | 298541 0.1422% | $2.95M | 1 | 14 | +118.24% |
| Thackray Helen M. | Chief R&D Officer | 272139 0.1297% | $2.69M | 1 | 3 | +42.26% |
| Doyle Anthony | Chief Financial Officer | 266744 0.1271% | $2.64M | 3 | 1 | +65.78% |
| FEATHERINGILL WILLIAM W | director, 10 percent owner | 231538 0.1103% | $2.29M | 3 | 4 | <0.0001% |
| STAAB THOMAS R II | Senior Vice President and CFO | 125176 0.0596% | $1.24M | 0 | 46 | |
| 14159 capital (GP), LLC | 10 percent owner | 120828 0.0576% | $1.19M | 3 | 3 | +289.09% |
| Cohen Fred E | director | 119410 0.0569% | $1.18M | 0 | 1 | |
| Hutson Nancy J | director | 86638 0.0413% | $856,849.82 | 3 | 4 | +71.35% |
| Baker Bros. Capital (GP), LLC | 10 percent owner | 71997 0.0343% | $712,050.33 | 3 | 3 | +289.09% |
| MILANO VINCENT | director | 66997 0.0319% | $662,600.33 | 2 | 0 | +14.91% |
| BENNETT J CLAUDE | Chief Operating Officer | 65730 0.0313% | $650,069.70 | 2 | 5 | <0.0001% |
| BUGG CHARLES E | director | 62439 0.0297% | $617,521.71 | 0 | 3 | |
| Jensen Peder | director | 60000 0.0286% | $593,400.00 | 4 | 0 | +3.75% |
| Galson Steven K | director | 51551 0.0246% | $509,839.39 | 1 | 0 | +35.35% |
| INGRAM ROBERT ALEXANDER | director | 48088 0.0229% | $475,590.32 | 1 | 0 | +118.24% |
| MONTGOMERY JOHN A | director | 46785 0.0223% | $462,703.65 | 0 | 1 | |
| LEVIN ALAN G | director | 44951 0.0214% | $444,565.39 | 1 | 0 | +16.74% |
| Sniecinski Megan | Chief Business Officer | 45000 0.0214% | $445,050.00 | 1 | 0 | +118.24% |
| Erck Stanley C | director | 40000 0.0191% | $395,600.00 | 1 | 0 | +454.8% |
| Sheridan William P | Chief Medical Officer | 37954 0.0181% | $375,365.06 | 1 | 16 | +240.53% |
| McKee Amy E | director | 27831 0.0133% | $275,248.59 | 0 | 1 | |
| LEE KENNETH B JR | director | 24252 0.0116% | $239,852.28 | 1 | 2 | +118.24% |
| Baker / Tisch Capital (GP), LLC | 10 percent owner | 17241 0.0082% | $170,513.49 | 3 | 3 | +289.09% |
| Grant Stuart | SR VP & CFO | 14717 0.007% | $145,551.13 | 2 | 10 | +102.99% |
| McCullough David | VP | 13926 0.0066% | $137,728.14 | 0 | 4 | |
| Jones Michael L | Exec. Director, Finance - PAO | 10753 0.0051% | $106,347.17 | 0 | 3 | |
| SANDERS CHARLES A | director | 7000 0.0033% | $69,230.00 | 2 | 0 | <0.0001% |
| ALEXANDER W JAMES | SR. VP, Chief Medical Officer | 3659 0.0017% | $36,187.51 | 2 | 0 | <0.0001% |
| DARWIN MICHAEL A | Principal Accounting Officer | 3048 0.0015% | $30,144.72 | 2 | 2 | <0.0001% |
| HOROVITZ ZOLA P | director | 3000 0.0014% | $29,670.00 | 0 | 4 | |
| SEIDENBERG BETH C | director | 3000 0.0014% | $29,670.00 | 1 | 0 | <0.0001% |
| ASELAGE STEVE | director | 2500 0.0012% | $24,725.00 | 4 | 0 | +42.97% |
| RIGGS RANDALL B | Senior VP Business Development | 1928 0.0009% | $19,067.92 | 2 | 1 | <0.0001% |
| Nugent Jonathan M | VP Corp Communications | 508 0.0002% | $5,024.12 | 2 | 1 | <0.0001% |
| Mills Mike | Principal Accounting Officer | 0 0% | $0 | 0 | 4 | |
| ABERCROMBIE GEORGE B | 0 0% | $0 | 2 | 8 | +230.41% | |
| Powell Lynne | Senior VP - CCO | 0 0% | $0 | 0 | 15 |
BioCryst Pharmaceuticals, Inc. (BCRX) | $21,345,882 | 83 | 94.45% | $2.08B |
$54,590,806 | 65 | 21.84% | $2.02B | |
$47,419,530 | 58 | 17.20% | $2.33B | |
$1,376,668 | 53 | 18.46% | $1.71B | |
$613,304,943 | 46 | 11.85% | $2.24B | |
$105,696,475 | 44 | 10.07% | $2.03B | |
$1,603,489 | 30 | 98.90% | $2.24B | |
$8,195,601 | 23 | -12.08% | $1.97B | |
$18,854,717 | 21 | 22.51% | $2.12B | |
$135,656,796 | 20 | 30.66% | $1.97B | |
$154,554,190 | 14 | 29.60% | $1.93B | |
$103,194,328 | 13 | 9.02% | $2.22B | |
$94,976,497 | 10 | -10.72% | $2.08B | |
$2,859,892 | 10 | 29.21% | $2.18B | |
$44,805,526 | 9 | 57.04% | $1.8B | |
$93,268,646 | 8 | -37.22% | $1.97B | |
$4,623,072 | 7 | 11.07% | $2.31B | |
$666,380 | 5 | -16.60% | $2.3B | |
$5,000,000 | 1 | -22.84% | $2.06B |
| Increased Positions | 194 | +52.15% | 72M | +31.82% |
| Decreased Positions | 169 | -45.43% | 55M | -24.05% |
| New Positions | 82 | New | 35M | New |
| Sold Out Positions | 59 | Sold Out | 25M | Sold Out |
| Total Postitions | 397 | +6.72% | 245M | +7.77% |
| Vanguard Group Inc | $163,432.00 | 10.33% | 21.79M | +1M | +6.07% | 2025-09-30 |
| Blackrock, Inc. | $159,344.00 | 10.07% | 21.25M | -179,973 | -0.84% | 2025-09-30 |
| Deerfield Management Company, L.P. | $91,268.00 | 5.77% | 12.17M | +7M | +159.36% | 2025-09-30 |
| State Street Corp | $73,556.00 | 4.65% | 9.81M | +1M | +15.31% | 2025-09-30 |
| Kynam Capital Management, Lp | $70,427.00 | 4.45% | 9.39M | +926,528 | +10.95% | 2025-09-30 |
| Ubs Group Ag | $44,758.00 | 2.83% | 5.97M | +353,086 | +6.29% | 2025-09-30 |
| Alkeon Capital Management Llc | $40,980.00 | 2.59% | 5.46M | -250,000 | -4.38% | 2025-09-30 |
| Arrowstreet Capital, Limited Partnership | $39,195.00 | 2.48% | 5.23M | +947,431 | +22.14% | 2025-09-30 |
| Morgan Stanley | $39,022.00 | 2.47% | 5.2M | -126,720 | -2.38% | 2025-09-30 |
| Geode Capital Management, Llc | $37,892.00 | 2.39% | 5.05M | -2,303 | -0.05% | 2025-09-30 |